We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Imaging Informatics Provider Announces FDA Clearance of New Platform

By MedImaging International staff writers
Posted on 08 Sep 2015
Print article
A new clinical decision support platform for enterprise Picture Archiving and Communication System (PACS) and Vendor Neutral Archives (VNA) has received US Food and Drug Administration (FDA) 510 (k) clearance.

The platform was designed to integrate and align with enterprise PACS and VNA systems using industry-standard formats such as the US American College of Radiology (ACR) Imaging 3.0 initiative.

The platform was developed by HealthMyne (Madison, WI, USA), an imaging informatics company, and is intended to help radiologists provide diagnostic imaging data to clinicians before and after performing an imaging exam during the clinical workflow.

HealthMyne’s image data mining platforms can help radiologist and oncologists increase their workflow efficiency by automating data capture, and structured reports. The platform will provide integrated patient progression timelines, and analytics and enable clinicians to compare data for an individual patient with a patient cohort. HealthMyne’s analytic tools are also intended to help researchers explore quantitative imaging biomarkers, and support improved clinical trials of innovative therapies.

Praveen Sinha, CEO of HealthMyne, said, “Having a strong diagnostic imaging platform cleared by the FDA is the first step in our vision of bringing imaging informatics to mainstream healthcare. Significant achievements are being realized elsewhere through clinical data aggregation and analysis, yet imaging has gone largely untapped. As an example, the potential impact of streamlined patient cohort comparison on personalized medicine is truly exciting.”

Related Links:

HealthMyne


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Fetal Monitor
Avante Compact II
New
Compact C-Arm
Arcovis DRF-C S21
Ultrasound Table
Powered Ultrasound Table-Flat Top

Print article

Channels

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more